ANAB
BULLISH
$64.81
Live
AnaptysBio, Inc. · NASDAQ
Target $76.58
(+18.2%)
$15.32
52W Range
$66.66
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.86B
P/E
N/A
ROE
-24.5%
Profit margin
-5.6%
Debt/Equity
7.81
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
87%
ANAB's Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 2/9, indicating significant distress risk, and no Altman Z-Score available, which raises red flags for solvency. Despite this, the company exhibits extraordinary growth momentum with 151% YoY revenue growth and a stellar 319.4% YoY EPS growth, supported by consistent earnings beat rates and large positive surprises. The stock trades at a premium valuation (Price/Sales: 7.94, Price/Book: 48.80), but this is justified by its high-growth biotech profile and strong analyst consensus. Insider selling activity is bearish, but the magnitude of recent earnings upside and market momentum suggest underlying strength. The overall picture reflects a high-risk, high-reward speculative opportunity.
Key Strengths
Exceptional 151.10% YoY revenue growth and 319.4% YoY EPS growth
Strong earnings beat rate (3/4 in last 4 quarters) with average surprise of 75.37%
High operating margin (61.80%) despite negative net profit margin
Analyst consensus of 'strong_buy' with a target price of $75.33 (17.5% upside)
Significant 1-year price appreciation (+284.9%) and strong momentum (17.3% in 1 month)
Key Risks
Piotroski F-Score of 2/9 indicates severe financial distress and weak operational health
Debt/Equity ratio of 7.81 is extremely high, signaling financial leverage risk
Negative ROE (-24.49%) and negative net profit margin (-5.64%) despite strong operating performance
Insider selling of $3.12M in last 6 months, including CEO and CFO, suggesting lack of confidence
No Graham Number or intrinsic value estimate, and no dividend, making valuation purely growth-based
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
50
Moderate
55
88
76
32
0
AI Verdict
bullish
Key drivers: Exceptional revenue and earnings growth, Strong analyst consensus and target price upside, High momentum and recent price appreciation, Positive earnings surprises and beat rates, High operating margin despite net losses
Confidence
85%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- High growth justifies premium valuation in biotech sector
- Price/Sales of 7.94 is below sector average (164.77 P/E, but P/S not directly comparable)
- Growth premium is supported by strong execution
Watchpoints
- No Graham Number or intrinsic value estimate available
- Price/Book of 48.80 is extremely high
- Negative net margin and ROE undermine traditional valuation metrics
Future
88/100
Ref Growth rates
Positives
- 151.10% YoY revenue growth and 319.4% YoY EPS growth
- Consistent earnings beat rate (3/4 in last 4 quarters)
- Large positive earnings surprises (avg +75.37%)
- Strong Q/Q EPS growth (+203.8%)
- High growth expectations priced in by market
Watchpoints
- No forward P/E or PEG available
- Negative net margin may persist if R&D costs remain high
- Sustained growth may be difficult to maintain at current pace
Past
76/100
Ref Historical trends
Positives
- 25 quarters of earnings history with consistent beat patterns
- Recent trend shows improving earnings trajectory (from -1.70 to +1.58)
- Multiple quarters with surprise >100% (e.g., +141.6%, +129.6%)
- Improving EPS progression over time
- Strong recovery from prior losses
Watchpoints
- Historical losses in early quarters (e.g., -1.74, -1.89)
- Negative EPS in 12 of 25 quarters
- Significant negative surprises in past (e.g., -88.4%, -83.5%)
Health
32/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High operating margin (61.80%) indicates strong operational efficiency
- Current and quick ratios (9.07 and 8.95) suggest strong liquidity
- Positive operating cash flow (implied by strong margins)
Watchpoints
- Piotroski F-Score of 2/9 indicates severe financial distress
- Debt/Equity of 7.81 is dangerously high
- Negative ROE (-24.49%) and ROA (7.06%) despite positive ROA
- No Altman Z-Score available, but low Piotroski score implies distress risk
- Negative net profit margin (-5.64%) despite positive operating margin
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout
- Payout ratio of 0.00%
- Dividend strength of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$64.81
Analyst Target
$76.58
Upside/Downside
+18.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANAB and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
Primary
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
GRAL
GRAIL, Inc.
Peer
|
+234.0% | +234.0% | +100.6% | -31.0% | -1.5% | -17.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
ESTA
Establishment Labs Holdings Inc.
Peer
|
-10.1% | -12.1% | +127.1% | +54.6% | -10.2% | +5.6% |
ANA
AnaptysBio, Inc.
Primary
5Y
+227.2%
3Y
+183.1%
1Y
+284.9%
6M
+177.0%
1M
+17.3%
1W
+17.0%
GRA
GRAIL, Inc.
Peer
5Y
+234.0%
3Y
+234.0%
1Y
+100.6%
6M
-31.0%
1M
-1.5%
1W
-17.0%
ADU
Addus HomeCare Corporation
Peer
5Y
-6.0%
3Y
+1.0%
1Y
+11.6%
6M
-8.1%
1M
-10.1%
1W
-1.8%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
EST
Establishment Labs Holdings Inc.
Peer
5Y
-10.1%
3Y
-12.1%
1Y
+127.1%
6M
+54.6%
1M
-10.2%
1W
+5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-16.06
PEG Ratio
N/A
P/B Ratio
48.8
P/S Ratio
7.94
EV/Revenue
7.85
EV/EBITDA
38.02
Market Cap
$1.86B
Profitability
Profit margins and return metrics
Profit Margin
-5.64%
Operating Margin
61.8%
Gross Margin
42.04%
ROE
-24.49%
ROA
7.06%
Growth
Revenue and earnings growth rates
Revenue Growth
+151.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
7.81
High debt
Current Ratio
9.07
Strong
Quick Ratio
8.95
Excellent
Cash/Share
$10.84
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-03-03
$1.58
+69.3% surprise
2025-11-04
$0.52
+141.6% surprise
2025-08-06
$-1.34
+15.3% surprise
Healthcare Sector Comparison
Comparing ANAB against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-24.49%
This Stock
vs
-88.14%
Sector Avg
-72.2%
(Below Avg)
Profit Margin
-5.64%
This Stock
vs
-16.28%
Sector Avg
-65.4%
(Weaker)
Debt to Equity
7.81
This Stock
vs
2.66
Sector Avg
+193.4%
(Higher)
Revenue Growth
151.1%
This Stock
vs
124.04%
Sector Avg
+21.8%
(Fast Growth)
Current Ratio
9.07
This Stock
vs
4.47
Sector Avg
+102.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | |
|
GRAL
GRAIL, Inc.
|
BEARISH | $1.87B | - | -16.1% | -277.5% | $45.63 | Compare |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | Compare |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
|
ESTA
Establishment Labs Holdings Inc.
|
BEARISH | $1.82B | - | -133.3% | -24.2% | $62.01 | Compare |
ANAB
AnaptysBio, Inc.
BULLISH
Mkt Cap
$1.9B
P/E
-
ROE
-24.5%
Price
$64.81
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-11 | LOUMEAU ERIC JOSEPH | Officer | Option Exercise | 10,000 | $297,000 |
| 2026-02-11 | LOUMEAU ERIC JOSEPH | Officer | Sale | 10,000 | $540,000 |
| 2026-01-15 | MARQUET MAGDA | Director | Option Exercise | 11,000 | $287,210 |
| 2026-01-15 | MARQUET MAGDA | Director | Sale | 11,000 | $530,531 |
| 2026-01-08 | MULROY DENNIS MICHAEL CPA | Chief Financial Officer | Sale | 2,515 | $112,446 |
| 2026-01-08 | FAGA DANIEL R | Chief Executive Officer | Sale | 14,281 | $638,504 |
| 2026-01-08 | LIZZUL PAUL F. | Officer | Sale | 3,650 | $163,192 |
| 2026-01-08 | LOUMEAU ERIC JOSEPH | Officer | Sale | 2,210 | $98,809 |
| 2026-01-07 | MULROY DENNIS MICHAEL CPA | Chief Financial Officer | Stock Award | 6,700 | - |
| 2026-01-07 | FAGA DANIEL R | Chief Executive Officer | Stock Award | 26,838 | - |
| 2026-01-07 | LIZZUL PAUL F. | Officer | Stock Award | 8,525 | - |
| 2026-01-07 | LOUMEAU ERIC JOSEPH | Officer | Stock Award | 5,888 | - |
| 2026-01-07 | MULROY DENNIS MICHAEL CPA | Chief Financial Officer | Sale | 1,908 | $86,070 |
| 2026-01-07 | FAGA DANIEL R | Chief Executive Officer | Sale | 9,202 | $415,102 |
| 2026-01-07 | LIZZUL PAUL F. | Officer | Sale | 2,235 | $100,821 |
LOUMEAU ERIC JOSEPH
Officer
2026-02-11
10,000 shares
·
$297,000
LOUMEAU ERIC JOSEPH
Officer
2026-02-11
10,000 shares
·
$540,000
MARQUET MAGDA
Director
2026-01-15
11,000 shares
·
$287,210
MARQUET MAGDA
Director
2026-01-15
11,000 shares
·
$530,531
MULROY DENNIS MICHAEL CPA
Chief Financial Officer
2026-01-08
2,515 shares
·
$112,446
FAGA DANIEL R
Chief Executive Officer
2026-01-08
14,281 shares
·
$638,504
LIZZUL PAUL F.
Officer
2026-01-08
3,650 shares
·
$163,192
LOUMEAU ERIC JOSEPH
Officer
2026-01-08
2,210 shares
·
$98,809
MULROY DENNIS MICHAEL CPA
Chief Financial Officer
2026-01-07
6,700 shares
FAGA DANIEL R
Chief Executive Officer
2026-01-07
26,838 shares
LIZZUL PAUL F.
Officer
2026-01-07
8,525 shares
LOUMEAU ERIC JOSEPH
Officer
2026-01-07
5,888 shares
MULROY DENNIS MICHAEL CPA
Chief Financial Officer
2026-01-07
1,908 shares
·
$86,070
FAGA DANIEL R
Chief Executive Officer
2026-01-07
9,202 shares
·
$415,102
LIZZUL PAUL F.
Officer
2026-01-07
2,235 shares
·
$100,821
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
12 analysts
Wedbush
2026-03-12
Outperform
Outperform
Truist Securities
2026-03-09
Hold
Hold
Stifel
2026-03-05
Buy
Buy
Barclays
2026-03-04
Overweight
Overweight
HC Wainwright & Co.
2026-03-04
Buy
Buy
Barclays
2026-01-20
Overweight
Overweight
Barclays
2025-12-17
Overweight
Overweight
Stifel
2025-12-11
Buy
Buy
Wedbush
2025-11-24
Outperform
Outperform
HC Wainwright & Co.
2025-11-24
Buy
Buy
Past News Coverage
Recent headlines mentioning ANAB from our newsroom.
Newest → oldest
No matching news yet.